Clinically significant adverse reactions (incidence unknown): Hepatic function disorders and jaundice: Hepatic function disorders accompanied by elevation of AST (GOT), ALT (GPT), γ-GTP or Al-P, or jaundice may occur. In the event of such abnormal findings, administration should be discontinued and appropriate measures should be taken.
Other adverse reactions: (see Table 3).
Click on icon to see table/diagram/image
View ADR Reporting Link
Sign Out